Immunomodulatory sphingosine-1-phosphates as plasma biomarkers of Alzheimer’s disease and vascular cognitive impairment
There has been ongoing research impetus to uncover novel blood-based diagnostic and prognostic biomarkers for Alzheimer’s disease (AD), vascular dementia (VaD), and related cerebrovascular disease (CEVD)-assoc...Alzheimer's Research & Therapy 2020 12:122Measurement of CSF core Alzheimer disease biomarkers for routine clinical diagnosis: do fresh vs frozen samples differ?
Cerebrospinal fluid (CSF) amyloid-beta (Aβ) 42/40 ratio, threonine-181-phosphorylated-tau (p-tau), and total-tau (t-tau) represent core biomarkers of Alzheimer disease (AD). The recent availability of automate...Alzheimer's Research & Therapy 2020 12:121Differential diagnostic value of total alpha-synuclein assay in the cerebrospinal fluid between Alzheimer’s disease and dementia with Lewy bodies from the prodromal stage
Several studies have investigated the value of alpha-synuclein assay in the cerebrospinal fluid (CSF) of Alzheimer’s disease (AD) and dementia with Lewy bodies (DLB) patients in the differential diagnosis of t...Alzheimer's Research & Therapy 2020 12:120Accelerated long-term forgetting in healthy older adults predicts cognitive decline over 1 year
Here, we address a pivotal factor in Alzheimer’s prevention—identifying those at risk early, when dementia can still be avoided. Recent research highlights an accelerated forgetting phenotype as a risk factor ...Alzheimer's Research & Therapy 2020 12:119Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology
Blood-based biomarkers for Alzheimer’s disease (AD) might facilitate identification of participants for clinical trials targeting amyloid beta (Abeta) accumulation, and aid in AD diagnostics. We examined the p...Alzheimer's Research & Therapy 2020 12:118Associations between vascular risk factors and subsequent Alzheimer’s disease in older adults
The clinical guidelines related to the primary prevention of Alzheimer’s disease (AD) have focused on the management of vascular risk factors. However, the link between vascular risk factors and AD in older ad...Alzheimer's Research & Therapy 2020 12:117Energy intake and expenditure in patients with Alzheimer’s disease and mild cognitive impairment: the NUDAD project
Malnutrition is common in patients with Alzheimer’s disease (AD) dementia and mild cognitive impairment (MCI) and is associated with institutionalization and increased mortality. Malnutrition is the result of ...Alzheimer's Research & Therapy 2020 12:116Associations between social and intellectual activities with cognitive trajectories in Chinese middle-aged and older adults: a nationally representative cohort study
Associations between the frequency of social and intellectual activities and cognitive trajectories are understudied in Chinese middle-aged and older adults. We aimed to examine this association in a nationall...Alzheimer's Research & Therapy 2020 12:115Principal components of tau positron emission tomography and longitudinal tau accumulation in Alzheimer’s disease
We aimed to investigate the clinical correlates of principal components (PCs) of tau positron emission tomography (PET) and their predictability for longitudinal changes in tau accumulation in Alzheimer’s dise...Alzheimer's Research & Therapy 2020 12:114Age and APOE genotype affect the relationship between objectively measured physical activity and power in the alpha band, a marker of brain disease
Electrophysiological studies show that reductions in power within the alpha band are associated with the Alzheimer’s disease (AD) continuum. Physical activity (PA) is a protective factor that has proved to red...Alzheimer's Research & Therapy 2020 12:113Measuring cortical mean diffusivity to assess early microstructural cortical change in presymptomatic familial Alzheimer’s disease
There is increasing interest in improving understanding of the timing and nature of early neurodegeneration in Alzheimer’s disease (AD) and developing methods to measure this in vivo. Autosomal dominant famili...Alzheimer's Research & Therapy 2020 12:112Neurofilament light chain in the vitreous humor of the eye
Neurofilament light chain (NfL) is a promising biomarker of neurodegeneration in the cerebrospinal fluid and blood. This study investigated the presence of NfL in the vitreous humor and its associations with a...Alzheimer's Research & Therapy 2020 12:111A phase II randomized trial of sodium oligomannate in Alzheimer’s dementia
Sodium oligomannate (GV-971), a marine-derived oligosaccharide, is a novel agent that may improve cognition in AD patients.Alzheimer's Research & Therapy 2020 12:110Mesenchymal stem cell-derived exosome: a promising alternative in the therapy of Alzheimer’s disease
Alzheimer’s disease (AD) has been a devastating public health with the development of global aging. Approaches for reducing the current AD epidemic are becoming a primary focus of human healthcare due to the l...Alzheimer's Research & Therapy 2020 12:109Amyloid-β1–43 cerebrospinal fluid levels and the interpretation of APP, PSEN1 and PSEN2 mutations
Alzheimer’s disease (AD) mutations in amyloid precursor protein (APP) and presenilins (PSENs) could potentially lead to the production of longer amyloidogenic Aβ peptides. Amongst these, Aβ1–43 is more prone to a...Alzheimer's Research & Therapy 2020 12:108Subjective cognitive decline, anxiety symptoms, and the risk of mild cognitive impairment and dementia
Subjective cognitive decline (SCD) and anxiety symptoms both predict neurocognitive disorders, but the two correlate strongly with each other. It is unclear whether they reflect two independent disease process...Alzheimer's Research & Therapy 2020 12:107Association of carotid and intracranial stenosis with Alzheimer’s disease biomarkers
To clarify whether atherosclerosis of the carotid and intracranial arteries is related to Alzheimer’s disease (AD) pathology in vivo, we investigated the associations of carotid and intracranial artery stenosi...Alzheimer's Research & Therapy 2020 12:106T2 heterogeneity: a novel marker of microstructural integrity associated with cognitive decline in people with mild cognitive impairment
Early Alzheimer’s disease (AD) diagnosis is vital for development of disease-modifying therapies. Prior to significant brain tissue atrophy, several microstructural changes take place as a result of Alzheimer’...Alzheimer's Research & Therapy 2020 12:105The Latin American Spanish version of the Face-Name Associative Memory Exam is sensitive to cognitive and pathological changes in preclinical autosomal dominant Alzheimer’s disease
To determine whether performance on the Latin American Spanish version of the Face-Name Associative Memory Exam (LAS-FNAME) can differentiate between cognitively intact carriers of an autosomal dominant Alzhei...Alzheimer's Research & Therapy 2020 12:104Analysis of brain region-specific co-expression networks reveals clustering of established and novel genes associated with Alzheimer disease
Identifying and understanding the functional role of genetic risk factors for Alzheimer disease (AD) has been complicated by the variability of genetic influences across brain regions and confounding with age-...Alzheimer's Research & Therapy 2020 12:103Prenatal to early postnatal neurotrophic treatment prevents Alzheimer-like behavior and pathology in mice
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder of middle-aged to old individuals. The pathophysiological process of AD is believed to begin many years before the emergence of clinical sym...Alzheimer's Research & Therapy 2020 12:102Effects of long-term sleep disruption on cognitive function and brain amyloid-β burden: a case-control study
Recent evidence indicates that disrupted sleep could contribute to the development of Alzheimer’s disease by influencing the production and/or clearance of the amyloid-β protein. We set up a case-control study...Alzheimer's Research & Therapy 2020 12:101The two faces of synaptic failure in AppNL-G-F knock-in mice
Intensive basic and preclinical research into Alzheimer’s disease (AD) has yielded important new findings, but they could not yet been translated into effective therapies. One of the reasons is the lack of ani...Alzheimer's Research & Therapy 2020 12:100Visual short-term memory relates to tau and amyloid burdens in preclinical autosomal dominant Alzheimer’s disease
Over the past decade, visual short-term memory (VSTM) binding tests have been shown to be one of the most sensitive behavioral indicators of Alzheimer’s disease (AD), especially when they require the binding o...Alzheimer's Research & Therapy 2020 12:99Repurposed agents in the Alzheimer’s disease drug development pipeline
Treatments are needed to address the growing prevalence of Alzheimer’s disease (AD). Clinical trials have failed to produce any AD drugs for Food and Drug Administration (FDA) approval since 2003, and the phar...Alzheimer's Research & Therapy 2020 12:98Normalization of CSF pTau measurement by Aβ40 improves its performance as a biomarker of Alzheimer’s disease
Alzheimer’s disease (AD)-related tauopathy can be measured with CSF phosphorylated tau (pTau) and tau PET. We aim to investigate the associations between these measurements and their relative ability to predic...Alzheimer's Research & Therapy 2020 12:97Amyloid precursor protein glycosylation is altered in the brain of patients with Alzheimer’s disease
The amyloid precursor protein (APP) is a transmembrane glycoprotein that undergoes alternative proteolytic processing. Its processing through the amyloidogenic pathway originates a large sAPPβ ectodomain fragm...Alzheimer's Research & Therapy 2020 12:96Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval
The body of evidence suggesting a causative, initiating role of beta amyloid (Aβ) in the pathogenesis of Alzheimer’s disease (AD) is substantial. Yet, only a few anti-amyloid agents have shown meaningful effic...Alzheimer's Research & Therapy 2020 12:95Estimating the potential for dementia prevention through modifiable risk factors elimination in the real-world setting: a population-based study
Preventing dementia onset is one of the global public health priorities: around 35% of dementia cases could be attributable to modifiable risk factors. These estimates relied on secondary data and did not cons...Alzheimer's Research & Therapy 2020 12:94Neurodegenerative changes in early- and late-onset cognitive impairment with and without brain amyloidosis
A substantial number of patients clinically diagnosed with Alzheimer’s disease do not harbor amyloid pathology. We analyzed the presence and extent of tau deposition and neurodegeneration in amyloid-positive (...Alzheimer's Research & Therapy 2020 12:93Association of glial and neuronal degeneration markers with Alzheimer’s disease cerebrospinal fluid profile and cognitive functions
Neuroinflammation has gained increasing attention as a potential contributing factor in the onset and progression of Alzheimer’s disease (AD). The objective of this study was to examine the association of sele...Alzheimer's Research & Therapy 2020 12:92The contribution of vascular risk factors in neurodegenerative disorders: from mild cognitive impairment to Alzheimer’s disease
Optimization of vascular risk factor control is emerging as an alternative approach to improve cognitive outcomes in Alzheimer’s disease, although its efficacy is still under debate. We aimed to investigate th...Alzheimer's Research & Therapy 2020 12:91Assessing what matters most to patients with or at risk for Alzheimer’s and care partners: a qualitative study evaluating symptoms, impacts, and outcomes
The What Matters Most (WMM) study was initiated to evaluate symptoms, AD-related impacts, treatment-related needs, preferences, and priorities among individuals with or at risk for Alzheimer’s disease (AD) and...Alzheimer's Research & Therapy 2020 12:90Intracranial alternating current stimulation facilitates neurogenesis in a mouse model of Alzheimer’s disease
Neurogenesis is significantly impaired in the brains of both human patients and experimental animal models of Alzheimer’s disease (AD). Although deep brain stimulation promotes neurogenesis, it is an invasive ...Alzheimer's Research & Therapy 2020 12:89CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer’s disease
The presynaptic protein neuregulin1 (NRG1) is cleaved by beta-site APP cleaving enzyme 1 (BACE1) in a similar way as amyloid precursor protein (APP) NRG1 can activate post-synaptic receptor tyrosine-protein ki...Alzheimer's Research & Therapy 2020 12:88Identification of potential blood biomarkers for early diagnosis of Alzheimer’s disease through RNA sequencing analysis
With demographic shifts toward older populations, the number of people with dementia is steadily increasing. Alzheimer’s disease (AD) is the most common cause of dementia, and no curative treatment is availabl...Alzheimer's Research & Therapy 2020 12:87The role of interleukin-33 in patients with mild cognitive impairment and Alzheimer’s disease
The neuroprotective role of interleukin (IL)-33 is supported by numerous preclinical studies, but it remains uninvestigated in clinical studies of Alzheimer’s disease (AD). We aimed to examine the association ...Alzheimer's Research & Therapy 2020 12:86Cardiovascular risk factors indirectly affect acute post-stroke cognition through stroke severity and prior cognitive impairment: a moderated mediation analysis
Cognitive impairment is an important consequence of stroke and transient ischaemic attack, but its determinants are not fully understood. Simple univariable or multivariable models have not shown clinical util...Alzheimer's Research & Therapy 2020 12:85Longitudinal changes in EEG power, sleep cycles and behaviour in a tau model of neurodegeneration
Disturbed sleep is associated with cognitive decline in neurodegenerative diseases such as Alzheimer’s disease (AD) and frontotemporal dementia (FTD). The progressive sequence of how neurodegeneration affects ...Alzheimer's Research & Therapy 2020 12:84CSF total tau/α-synuclein ratio improved the diagnostic performance for Alzheimer’s disease as an indicator of tau phosphorylation
Recently, several studies suggested potential involvements of α-synuclein in Alzheimer’s disease (AD) pathophysiology. Higher concentrations of α-synuclein were reported in cerebrospinal fluid (CSF) of AD pati...Alzheimer's Research & Therapy 2020 12:83Quantitative EEG as a biomarker in mild cognitive impairment with Lewy bodies
To investigate using quantitative EEG the (1) differences between patients with mild cognitive impairment with Lewy bodies (MCI-LB) and MCI with Alzheimer’s disease (MCI-AD) and (2) its utility as a potential ...Alzheimer's Research & Therapy 2020 12:82One third of dementia cases can be prevented within the next 25 years by tackling risk factors. The case “for” and “against”
Recently, it has been suggested that up to a third of the dementia cases might be preventable. While prevention is always better than cure, this is particularly important in the field of dementia, as current i...Alzheimer's Research & Therapy 2020 12:81Cathepsin D regulates cerebral Aβ42/40 ratios via differential degradation of Aβ42 and Aβ40
Cathepsin D (CatD) is a lysosomal protease that degrades both the amyloid β-protein (Aβ) and the microtubule-associated protein, tau, and has been genetically linked to late-onset Alzheimer disease (AD). Here,...Alzheimer's Research & Therapy 2020 12:80The insula, a grey matter of tastes: a volumetric MRI study in dementia with Lewy bodies
Despite the growing number of discoveries during the past decades about its functions, the insula remains a mysterious ‘island’. In addition to its involvement in basic functions such as gustation and interoce...Alzheimer's Research & Therapy 2020 12:79
viernes, 9 de octubre de 2020
Alzheimer's Research & Therapy | Articles
Alzheimer's Research & Therapy | Articles
Suscribirse a:
Enviar comentarios (Atom)
.png)
No hay comentarios:
Publicar un comentario